Web24 sep. 2015 · The IPF research landscape has changed and the design and conduct of clinical trials in IPF requires some radical rethinking. ... King Jr TE, et al. Idiopathic … WebStudy design decisions, in particular cohort enrichment strategies, have a substantial impact on sample size requirements for IPF clinical trials using time-to-event primary end …
biolincc.nhlbi.nih.gov
Web27 jun. 2024 · The design of this early-phase trial is novel and overcomes the limitations of most previous early-phase studies in IPF. The trial was small, fast (treatment duration 12 … Web26 okt. 2024 · The key secondary endpoint is the time to the first occurrence of any of the components of the composite endpoint: time to first acute IPF/ILD exacerbation, first … birmingham city council instagram
Clinical Trials in IPF: What Are the Best Endpoints?
Web30 sep. 2014 · Karen is a regulatory strategy and drug development team consultant with 20 years of industry experience with Cubist, Merck, … Web7 aug. 2014 · IPF clinical trial design and endpoints S. Nathan, K. Meyer Published 7 August 2014 Medicine Current Opinion in Pulmonary Medicine Purpose of review There … WebA decline in forced vital capacity (FVC) is indicative of disease progression in patients with IPF and change in FVC is the most commonly used endpoint in clinical trials [ 7, 8 ]. A decline in FVC of 5% or 10% of the predicted value over 6–12 months has been associated with increased mortality in patients with IPF [ 7, 9, 10 ]. d and n tyres feeny